Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) Short Interest Update

Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) was the target of a large decline in short interest in May. As of May 29th, there was short interest totaling 85,189 shares, a decline of 69.4% from the May 14th total of 278,140 shares. Based on an average daily trading volume, of 417,303 shares, the short-interest ratio is presently 0.2 days. Currently, 3.3% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cuprina Holdings (Cayman) in a research note on Friday, April 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Cuprina Holdings (Cayman) Stock Up 64.7%

Shares of CUPR traded up $1.56 during mid-day trading on Friday, reaching $3.97. 83,240,193 shares of the stock traded hands, compared to its average volume of 294,691. The business has a fifty day simple moving average of $2.54. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.35 and a quick ratio of 2.35. Cuprina Holdings has a 1 year low of $1.76 and a 1 year high of $76.00.

Cuprina Holdings (Cayman) (NASDAQ:CUPR) last posted its quarterly earnings data on Monday, April 27th. The company reported ($0.40) earnings per share (EPS) for the quarter. The firm had revenue of $0.01 million for the quarter.

Cuprina Holdings (Cayman) Company Profile

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. We believe we will be able to build upon and leverage such expertise to develop innovative cosmeceutical products in the future.